Weiss Thomas W, Gold Deborah T, Silverman Stuart L, McHorney Colleen A
Merck & Co., Inc., West Point, PA 19486, USA.
Curr Med Res Opin. 2006 May;22(5):949-60. doi: 10.1185/030079906X104740.
To evaluate preferences for eight medication attributes that women may consider when evaluating prescription osteoporosis medications.
The eligible sample consisted of women aged 50 years or older who responded to the 2003 or 2004 Internet-based National Health and Wellness Survey as being diagnosed with osteoporosis, considering themselves at risk, or having a family history of osteoporosis. In this Internet survey (the PREFER survey), respondents were asked to: (1) force-rank order the eight attributes from one to eight according to their preferences and (2) separately rate the importance of each attribute on a Likert-type scale from 1 (extremely unimportant) to 7 (extremely important).
We collected 999 responses across 3 days from a sample of 3368 women and stopped compiling responses after achieving sample size targets. Drug effectiveness (e.g., ability to reduce the risk of fractures) was force ranked as the No. 1 preferred osteoporosis medication attribute by 37% of the sample. Side effects were force ranked as the No. 1 preferred medication attribute by 36% of the sample. Dosing frequency, dosing procedure, and formulation (i.e., how the drug is taken) were each force ranked as No. 1 by 2% or less of the sample. Drug effectiveness had the highest percentage of 'extremely important' responses (59%) followed by drug interactions (53%). Drug effectiveness was the highest-rated attribute (mean [S.D.] = 6.1 [1.6], median = 7), while dosing frequency was the lowest-rated attribute (mean [S.D.] = 4.7 [1.8], median = 5).
In our sample of women with a diagnosis of osteoporosis or at risk for osteoporosis, drug effectiveness was the most highly ranked and rated of eight osteoporosis medication attributes. Side effects and drug interactions were also highly ranked and rated. Healthcare providers should consider incorporating patient preferences for key medication attributes into their therapeutic decision-making processes.
评估女性在评估处方骨质疏松症药物时可能考虑的八种药物属性的偏好。
符合条件的样本包括年龄在50岁及以上的女性，她们在2003年或2004年基于互联网的全国健康与 Wellness 调查中回复称被诊断患有骨质疏松症、认为自己有风险或有骨质疏松症家族史。在这项互联网调查（PREFER 调查）中，受访者被要求：(1) 根据自己的偏好对这八个属性从一到八进行强制排序；(2) 分别在从1（极其不重要）到7（极其重要）的李克特量表上对每个属性的重要性进行评分。
我们在3天内从3368名女性样本中收集了999份回复，并在达到样本量目标后停止收集回复。药物有效性（例如降低骨折风险的能力）被37%的样本强制列为首选的骨质疏松症药物属性。副作用被36%的样本强制列为首选的药物属性。给药频率、给药程序和剂型（即药物的服用方式）在样本中被列为首选的比例均为2%或更低。药物有效性获得“极其重要”回复的百分比最高（59%），其次是药物相互作用（53%）。药物有效性是评分最高的属性（均值[标准差]=6.1[1.6]，中位数=7），而给药频率是评分最低的属性（均值[标准差]=4.7[1.8]，中位数=5）。
在我们诊断为骨质疏松症或有骨质疏松症风险的女性样本中，药物有效性在八种骨质疏松症药物属性中排名和评分最高。副作用和药物相互作用也排名和评分较高。医疗保健提供者应考虑将患者对关键药物属性的偏好纳入其治疗决策过程。
